Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25594480 | 0.97 | MEN1 (0.47) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL18133869 | 0.90 | MEN1 (0.39) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL13154267 | 0.90 | SIGMAR1 (0.40) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL22570050 | 0.90 | MEN1 (0.53) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL13069405 | 0.89 | MEN1 (0.43) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL24626947 | 0.88 | SIGMAR1 (0.42) | MEN1KMT2AOPRL1OPRM1 | |
| SCHEMBL22570041 | 0.87 | MEN1 (0.42) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL24480967 | 0.87 | MEN1 (0.39) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL107432 | 0.86 | OPRL1 (0.38) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL24185791 | 0.86 | OPRL1 (0.38) | MEN1KMT2ATRPV6OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20220396548-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2022-12-15 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11021470-B2 | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof | ARAXES PHARMA LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210078936-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20160318943-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEROF IN PREPARATION OF MEDICAMENT | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | MEN1 4007/4885KMT2A 1377/4885TRPV6 3560/4885 |
| US-20220396548-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | RNASEH1, NSUN3, SLC67A1 | MEN1 724/4885KMT2A 2267/4885TRPV6 2172/4885 |
| US-20210078936-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LPAR1, LPAR4, LIPA | MEN1 717/4885KMT2A 3353/4885TRPV6 1261/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | MEN1 427/4885KMT2A 3648/4885TRPV6 233/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MEN1 122/4885KMT2A 1296/4885TRPV6 4822/4885 |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | MEN1 3340/4885KMT2A 469/4885TRPV6 3172/4885 |
| US-20160318943-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEROF IN PREPARATION OF MEDICAMENT | MAVS, SARS1, IRF3 | MEN1 2349/4885KMT2A 3440/4885TRPV6 2196/4885 |
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCG2, NQO2 | MEN1 1105/4885KMT2A 2451/4885TRPV6 2080/4885 |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | MEN1 1901/4885KMT2A 3039/4885TRPV6 188/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MEN1 142/4885KMT2A 4008/4885TRPV6 1513/4885 |
| US-11021470-B2 | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof | KRAS, NRAS, HRAS | MEN1 102/4885KMT2A 755/4885TRPV6 4837/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MEN1 142/4885KMT2A 4008/4885TRPV6 1513/4885 |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | PHOSPHO1, SGMS1, ABCB4 | MEN1 1022/4885KMT2A 3485/4885TRPV6 1331/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | MEN1 2563/4885KMT2A 2222/4885TRPV6 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.